
    
      This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be
      conducted in two parts: the Dose Escalation Phase, and the Dose Expansion Phase

      The Dose Escalation Phase is no longer enrolling. The Dose Expansion Phase is commencing in
      the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC).
    
  